1. Expression of the organic cation/carnitine transporter family (Octn1,-2 and-3) in mdx muscle and heart: Implications for early carnitine therapy in Duchenne muscular dystrophy to improve cellular carnitine homeostasis.
- Author
-
Lamhonwah AM and Tein I
- Subjects
- Animals, Carnitine metabolism, Diaphragm metabolism, Homeostasis, Male, Mice, Mice, Inbred C57BL, Mice, Inbred mdx, Mitochondria, Heart metabolism, Mitochondria, Muscle metabolism, Muscle, Skeletal metabolism, Myocardium metabolism, RNA, Messenger biosynthesis, RNA, Messenger genetics, Carnitine chemistry, Carnitine therapeutic use, Muscle, Skeletal chemistry, Muscular Dystrophy, Duchenne drug therapy, Muscular Dystrophy, Duchenne genetics, Myocardium chemistry, Organic Cation Transport Proteins biosynthesis, Organic Cation Transport Proteins genetics, Solute Carrier Family 22 Member 5 biosynthesis, Solute Carrier Family 22 Member 5 genetics, Symporters biosynthesis, Symporters genetics
- Abstract
Introduction: Carnitine is essential for long-chain fatty acid oxidation in muscle and heart. Tissue stores are regulated by organic cation/Cn transporter plasmalemmal Octn2. We previously demonstrated low carnitine in quadriceps/gluteus and heart of adult mdx mice., Methods: We studied protein and mRNA expression of Octn2, mitochondrial Octn1 and peroxisomal Octn3 in adult male C57BL/10ScSn-DMD mdx/J quadriceps, heart, and diaphragm compared to C57BL/10SnJ mice., Results: We demonstrated reduction in mOctn2 expression on Western blot and similar expression of mOctn1 and mOctn3 in mdx quadriceps, heart and diaphragm. There was a significant upregulation of mOctn1 and mOctn2 mRNA by qRT-PCR in mdx quadriceps and of mOctn2 and mOctn3 mRNA in mdx heart. We showed upregulation of mdx mOctn1 and mOctn3 mRNA but no increase in protein expression., Discussion: Dystrophin deficiency likely disrupts Octn2 expression decreasing muscle carnitine uptake thus contributing to membranotoxic long-chain acyl-CoAs with sarcolemmal and organellar membrane oxidative injury providing a treatment rationale for early L-carnitine in DMD., Competing Interests: Declaration of Competing Interest Dr. Lamhonwah reports no conflict of interest. Dr. Lamhonwah contributed to the design of the study, analysis and interpretation of the data and to the review of the manuscript for intellectual content. Dr. Tein reports operating grants from the Foundation for Prader Willi Research, the Myositis Foundation, the Cure JM Foundation, and the Physicians’ Services Incorporated Foundation of Ontario none of which played a role in this study. Dr. Tein contributed to the design of the study, analysis and interpretation of the data and wrote the manuscript., (Copyright © 2020. Published by Elsevier B.V.)
- Published
- 2020
- Full Text
- View/download PDF